| 1 |
Gilloteaux DJ, Jamison JM, Summers JL, Taper HS. Xenografts on nude mouse diaphragm of human DU145 prostate carcinoma cells: mesothelium removal by outgrowths and angiogenesis. Ultrastruct Pathol 2022;:1-26. [PMID: 36165802 DOI: 10.1080/01913123.2022.2115596] [Reference Citation Analysis]
|
| 2 |
Klicka K, Grzywa TM, Mielniczuk A, Klinke A, Włodarski PK. The role of miR-200 family in the regulation of hallmarks of cancer. Front Oncol 2022;12:965231. [DOI: 10.3389/fonc.2022.965231] [Reference Citation Analysis]
|
| 3 |
McCoy P, Mangiola S, Macintyre G, Hutchinson R, Tran B, Pope B, Georgeson P, Hong MKH, Kurganovs N, Lunke S, Clarkson MJ, Cmero M, Kerger M, Stuchbery R, Chow K, Haviv I, Ryan A, Costello AJ, Corcoran NM, Hovens CM. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis 2021;24:1167-80. [PMID: 34108644 DOI: 10.1038/s41391-021-00379-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Karmakar D, Maity J, Mondal P, Shyam Chowdhury P, Sikdar N, Karmakar P, Das C, Sengupta S. E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9. Carcinogenesis 2020;41:1767-80. [PMID: 32386317 DOI: 10.1093/carcin/bgaa043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 5 |
Wang W, He Z, Kong Y, Liu Z, Gong L. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia. Clin Chim Acta 2021;519:10-7. [PMID: 33831421 DOI: 10.1016/j.cca.2021.03.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Roldán Gallardo FF, Quintar AA. The pathological growth of the prostate gland in atherogenic contexts. Exp Gerontol 2021;148:111304. [PMID: 33676974 DOI: 10.1016/j.exger.2021.111304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Chatrath A, Przanowska R, Kiran S, Su Z, Saha S, Wilson B, Tsunematsu T, Ahn JH, Lee KY, Paulsen T, Sobierajska E, Kiran M, Tang X, Li T, Kumar P, Ratan A, Dutta A. The pan-cancer landscape of prognostic germline variants in 10,582 patients. Genome Med 2020;12:15. [PMID: 32066500 DOI: 10.1186/s13073-020-0718-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 8 |
Basu S, Chaudhary A, Chowdhury P, Karmakar D, Basu K, Karmakar D, Chatterjee J, Sengupta S. Evaluating the role of hsa-miR-200c in reversing the epithelial to mesenchymal transition in prostate cancer. Gene 2020;730:144264. [PMID: 31759982 DOI: 10.1016/j.gene.2019.144264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 9 |
Wang R, Zhang M, Ou Z, He W, Chen L, Zhang J, He Y, Xu R, Jiang S, Qi L, Wang L. Long noncoding RNA DNM3OS promotes prostate stromal cells transformation via the miR-29a/29b/COL3A1 and miR-361/TGFβ1 axes. Aging (Albany NY) 2019;11:9442-60. [PMID: 31694982 DOI: 10.18632/aging.102395] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 10 |
Chatrath A, Przanowska R, Kiran S, Su Z, Saha S, Wilson B, Tsunematsu T, Ahn J, Lee KY, Paulsen T, Sobierajska E, Kiran M, Tang X, Li T, Kumar P, Ratan A, Dutta A. The Pan-Cancer Landscape of Prognostic Germline Variants in 10,582 Patients.. [DOI: 10.1101/19010264] [Reference Citation Analysis]
|
| 11 |
Albero-gonzález R, Hernández-llodrà S, Juanpere N, Lorenzo M, Lloret A, Segalés L, Duran X, Fumadó L, Cecchini L, Lloreta-trull J. Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status. Virchows Arch 2019;475:223-31. [DOI: 10.1007/s00428-019-02591-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 12 |
Greco F, Inferrera A, La Rocca R, Navarra M, Casciaro M, Grosso G, Gangemi S, Ficarra V, Mirone V. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. European Urology Focus 2019;5:497-507. [DOI: 10.1016/j.euf.2018.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Chakraborty B, Mondal P, Gajendra P, Mitra M, Das C, Sengupta S. Deciphering genetic regulation of CD14 by SP1 through characterization of peripheral blood mononuclear transcriptome of P. faiciparum and P. vivax infected malaria patients. EBioMedicine 2018;37:442-52. [PMID: 30337251 DOI: 10.1016/j.ebiom.2018.09.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 14 |
Li B, Jin X, Meng H, Hu B, Zhang T, Yu J, Chen S, Guo X, Wang W, Jiang W, Wang J. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget 2017;8:47849-60. [PMID: 28599307 DOI: 10.18632/oncotarget.18133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 15 |
Mccoy P, Mangiola S, Macintyre G, Hutchinson R, Tran B, Hong MK, Kurganovs N, Clarkson MJ, Cmero M, Kerger M, Stuchbery R, Chow K, Haviv I, Ryan A, Costello AJ, Corcoran NM, Hovens CM. MSH2 is Inactivated by Multiple Mechanisms in Prostate Tumors, Leading to a Distinct Immune Response and Clinical Outcome Compared to MSH2 Deficient Colorectal Cancer. SSRN Journal. [DOI: 10.2139/ssrn.3245216] [Reference Citation Analysis]
|
| 16 |
Dart DA, Uysal-Onganer P, Jiang WG. Prostate-specific PTen deletion in mice activates inflammatory microRNA expression pathways in the epithelium early in hyperplasia development. Oncogenesis 2017;6:400. [PMID: 29284790 DOI: 10.1038/s41389-017-0007-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 17 |
Bosutti A, Zanconati F, Grassi G, Dapas B, Passamonti S, Scaggiante B. Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem 2016;16:1385-402. [PMID: 27109021 DOI: 10.2174/1871520616666160425105257] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 18 |
McDermott N, Meunier A, Wong S, Buchete V, Marignol L. Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs. Clin Transl Radiat Oncol 2017;2:63-8. [PMID: 29658003 DOI: 10.1016/j.ctro.2017.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Hashemi M, Moradi N, Ziaee SA, Narouie B, Soltani MH, Rezaei M, Shahkar G, Taheri M. Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J Adv Res 2016;7:491-8. [PMID: 27222754 DOI: 10.1016/j.jare.2016.03.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 20 |
Lin YL, Deng QK, Wang YH, Fu XL, Ma JG, Li WP. Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy. Med Sci Monit 2015;21:3955-690. [PMID: 26683656 DOI: 10.12659/msm.896763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
